Sysmex (SSMXY) Projected to Post Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) is anticipated to announce its results after the market closes on Wednesday, August 5th. Analysts expect Sysmex to post earnings of $0.07 per share and revenue of $741.3960 million for the quarter. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The business had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sysmex Price Performance

SSMXY stock opened at $10.06 on Tuesday. The stock’s 50 day moving average is $9.25 and its two-hundred day moving average is $9.06. Sysmex has a 52-week low of $8.01 and a 52-week high of $16.83. The company has a market capitalization of $6.34 billion, a PE ratio of 26.48 and a beta of 1.05. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.